Browse Health
Allergy & Immunology Specialist, Internist
30 years of experience
Accepting new patients

Education ?

Medical School Score
Rosalind Franklin University (1980)
  • Currently 2 of 4 apples

Awards & Distinctions ?

Awards  
Patients' Choice Award (2009 - 2011, 2013)
Compassionate Doctor Recognition (2011 - 2013)
Associations
American Academy of Allergy Asthma and Immunology
American Board of Allergy and Immunology
American Board of Internal Medicine
Long Island Allergy and Asthma Society

Affiliations ?

Dr. Friedman is affiliated with 13 hospitals.

Hospital Affilations

Score

Rankings

  • Fountain Valley Regional Hospital & Medical Center
    17100 Euclid St, Fountain Valley, CA 92708
    • Currently 4 of 4 crosses
    Top 25%
  • Los Alamitos Medical Center
    3751 Katella Ave, Los Alamitos, CA 90720
    • Currently 4 of 4 crosses
    Top 25%
  • University of California, Irvine Medical Center
    1310 W Stewart Dr, Orange, CA 92868
    • Currently 4 of 4 crosses
    Top 25%
  • South Coast Medical Center/Adventist Health
    31872 Coast Hwy, Laguna Beach, CA 92651
    • Currently 4 of 4 crosses
    Top 25%
  • Anaheim Memorial Medical Center
    1111 W La Palma Ave, Anaheim, CA 92801
    • Currently 4 of 4 crosses
    Top 25%
  • Mission Hospital
    27700 Medical Center Rd, Mission Viejo, CA 92691
    • Currently 4 of 4 crosses
    Top 25%
  • Western Medical Center - Santa Ana
    1001 N Tustin Ave, Santa Ana, CA 92705
    • Currently 3 of 4 crosses
    Top 50%
  • Orange Coast Memorial Med Ctr
  • Lakewood Regional Med Ctr
  • Fountain Valley Reg Hosp & Med, Fountain Vly, Ca
  • Hoag Memorial Hospital Presbyterian
  • 1986
  • Solo Practice
  • Publications & Research

    Dr. Friedman has contributed to 5 publications.
    Title Efficacy and Safety of Low-dose Fluticasone Propionate Compared with Montelukast for Maintenance Treatment of Persistent Asthma.
    Date May 2002
    Journal Mayo Clinic Proceedings. Mayo Clinic
    Excerpt

    OBJECTIVE: To compare the long-term effects of an inhaled corticosteroid with those of a leukotriene modifier on measures of clinical efficacy, subject preference, and safety in patients with persistent asthma. PATIENTS AND METHODS: Between November 17, 1998, and May 26, 2000, we conducted a multicenter, randomized, double-blind, double-dummy, parallel-group study of patients aged 15 years or older with persistent asthma. The patients were symptomatic while taking short-acting beta2-agonists alone and were treated with fluticasone propionate (88 microg [2 puffs of 44 microg] twice daily) or montelukast (10 mg/d) for 24 weeks. Measures of pulmonary function, asthma symptoms, albuterol use, nighttime awakenings, physician assessments of efficacy, patient satisfaction, asthma-related quality of life, and safety were evaluated. RESULTS: A total of 522 patients were randomized to receive fluticasone or montelukast, and 395 patients completed the study. At end point, treatment with fluticasone significantly improved pulmonary function, asthma symptom scores, the percentage of symptom-free days, rescue albuterol use, and the number of nighttime awakenings due to asthma when compared with montelukast (P< or = .002, each comparison). Significantly more patients were satisfied with fluticasone therapy (83%) compared with montelukast therapy (66%) (P<.001), and fluticasone therapy was rated as effective by a significantly greater portion of physicians (67%) than was montelukast therapy (54%) (P<.001). Treatment with fluticasone significantly improved asthma-related quality-of-life measures compared with montelukast (P< or =.01). The incidence of asthma exacerbations was similar in the fluticasone (19 patients, 7%) and montelukast (21 patients, 8%) treatment groups, although slightly more patients in the montelukast group were withdrawn from the study because of asthma exacerbations (6% vs 4%, respectively). CONCLUSION: Long-term treatment with a low dose of inhaled fluticasone is more effective than oral montelukast as first-line maintenance therapy for the treatment of persistent asthma.

    Title Fluticasone Propionate Versus Zafirlukast: Effect in Patients Previously Receiving Inhaled Corticosteroid Therapy.
    Date December 2000
    Journal Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
    Excerpt

    BACKGROUND: The use of inhaled corticosteroids compared with leukotriene modifying drugs in the treatment of persistent asthma has not been extensively studied. OBJECTIVE: To compare the efficacy and safety of a low dose of fluticasone propionate (FP) and zafirlukast in patients previously maintained on inhaled corticosteroids. METHODS: Patients (> or = 12 years old; FEV1 = 60% to 85% of predicted) with persistent asthma who were previously treated with low doses of triamcinolone acetonide (TAA) 400 to 800 microg/day or beclomethasone dipropionate (BDP) 168 to 336 microg/day were randomized to treatment with FP aerosol 88 microg BID (FP, n = 221) or zafirlukast 20 mg BID (n = 216) over 6 weeks. RESULTS: Treatment with FP significantly increased the mean change at endpoint (the last post-baseline observation) in FEV1 (0.22 L versus 0.03 L, P < .001), morning PEF (17.8 versus 3.1 L/min, P = .004), evening PEF (16.7 versus 2.6 L/min, P = .002), the percentage of symptom-free days (16.2 versus 7.1%, P = .007), and the percentage of rescue-free days (23.4 versus 9.3%, P < .001), and significantly decreased rescue albuterol use (-0.66 puffs/day versus an increase of 0.27 puffs/day, P < .001) and combined symptom scores (-0.13 versus an increase of 0.08, P < .001) compared with zafirlukast. Treatment with FP maintained the percentage of awakening-free nights (-1.0 +/- 1.0); in contrast, treatment with zafirlukast reduced the percentage of awakening-free nights (-9.0 +/- 1.6, P < .001). A clinically meaningful difference (change of > or = 0.5; P < .001) was observed between FP and zafirlukast in the Asthma Quality of Life Questionnaire (AQLQ) global score and for each domain score except activity limitation (change of 0.3, P < .001). Significantly more patients in the zafirlukast group experienced an asthma exacerbation (n = 14) compared with FP-treated patients (n = 5, P = .035). Patients in the zafirlukast group were significantly more likely to be withdrawn due to lack of efficacy (P < .001). CONCLUSION: Switching patients from low doses of inhaled corticosteroids to a lower total microgram dose of FP improves pulmonary function, asthma symptoms, and quality of life, while switching to the leukotriene receptor antagonist zafirlukast may result in worsening of asthma control. This was indicated by the significant number of zafirlukast-treated patients who were dropped from the study due to lack of efficacy within 6 weeks of discontinuing inhaled corticosteroids.

    Title Once-daily Mometasone Furoate Dry Powder Inhaler in the Treatment of Patients with Persistent Asthma.
    Date May 2000
    Journal Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
    Excerpt

    BACKGROUND: Although inhaled glucocorticoids are recommended for all stages of persistent asthma, compliance with long-term therapy is often poor, leading to significant morbidity and mortality. A simplified, once-daily dosing regimen may foster improved compliance. Objective: To compare the efficacy and safety of once-daily (AM) administration of mometasone furoate dry powder inhaler (MF DPI) 200 microg and 400 microg with placebo in patients with asthma previously maintained only on short-acting inhaled beta-adrenergic receptor agonists. Methods: This was a 12-week, double-blind, placebo-controlled, parallel group study. The mean change from baseline to endpoint (last treatment visit) for FEV1 was the primary efficacy variable. Results: At endpoint, both doses of MF DPI were significantly more effective than placebo (P < or = .05) in improving FEV1. Based on morning peak expiratory flow rate, once-daily MF DPI 400 microg was more effective than placebo (P < or = .001) at endpoint. Both active treatments also demonstrated improvement at endpoint in asthma symptom scores, physician-evaluated response to therapy and use of rescue medication. Although both MF DPI dosages were efficacious, MF DPI 400 microg provided additional improvement in some measures of pulmonary function (eg, morning PEFR) when these agents were administered once daily in the morning. Both doses of MF DPI were well tolerated and treatment-related adverse events occurred at a similar incidence among the three treatment groups. Conclusions: The results of this study indicate that once-daily (AM) MF DPI provides a convenient and effective treatment option for patients with mild or moderate persistent asthma.

    Title Mycobacterium Avium-intracellulare: Cutaneous Presentations of Disseminated Disease.
    Date September 1988
    Journal The American Journal of Medicine
    Title An Improved Protocol for the Use of Troleandomycin (tao) in the Treatment of Steroid-requiring Asthma.
    Date August 1986
    Journal The Journal of Allergy and Clinical Immunology
    Excerpt

    An improved protocol was developed for the use of troleandomycin (TAO) in severe, steroid-requiring subjects with asthma. Compared to previous reports, this protocol uses a lower starting dose of TAO and a rapid steroid taper. Fifteen patients were treated with TAO following the new guidelines. Steroid requirements in the 15 patients dropped by 68% within 2 weeks, and 13 of the 15 patients were able to be maintained on alternate day steroids. In spite of rapid steroid taper, both FEV1 and mean FVC increased significantly (p less than 0.001). There was a low incidence of side effects and, in contrast to previous reports on TAO, no patient had even a transient increase in cushingoid appearance. Glucose intolerance was observed initially in three patients but resolved with continued steroid taper. Transient liver-enzyme elevation was noted in four patients and in each case reversed with a reduction in TAO dosage. The revised protocol is associated with an improved risk-benefit ratio. New guidelines are presented for the use of TAO in severe steroid-requiring subjects with asthma.

    Similar doctors nearby

    Dr. Ellen Reich

    Allergy & Immunology
    22 years experience
    Fountain Valley, CA

    Dr. Purvee Gandhi

    Allergy & Immunology
    7 years experience
    Costa Mesa, CA

    Dr. Harvey Nguyen

    Allergy & Immunology
    43 years experience
    Westminster, CA

    Dr. Parvaneh Abadee-Amoli

    Pediatric Allergy & Immunology
    45 years experience
    Costa Mesa, CA

    Dr. Denis Yoshii

    Allergy & Immunology
    15 years experience
    Costa Mesa, CA

    Dr. Paul Qaqundah

    Allergy & Immunology
    49 years experience
    Huntington Beach, CA
    Search All Similar Doctors